File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Acarbose in NIDDM patients with poor control on conventional oral agents: A 24-week placebo-controlled study

TitleAcarbose in NIDDM patients with poor control on conventional oral agents: A 24-week placebo-controlled study
Authors
Issue Date1998
PublisherAmerican Diabetes Association. The Journal's web site is located at http://diabetes.diabetesjournals.org/
Citation
Diabetes Care, 1998, v. 21 n. 7, p. 1154-1158 How to Cite?
AbstractOBJECTIVE- To determine the efficacy of acarbose, compared with placebo, on the metabolic control of NIDDM patients inadequately controlled on maximal doses of conventional oral agents. RESEARCH DESIGN AND METHODS- In this three-center double-blind study, 90 Chinese NIDDM patients with persistent poor glycemic control despite maximal doses of sulfonylurea and metformin were randomly assigned to receive additional treatment with acarbose 100 mg thrice daily or placebo for 24 weeks, after 6 weeks of dietary reinforcement. Efficacy was assessed by changes in HbA(1c), fasting and 1-h postprandial plasma glucose and insulin levels, and fasting lipid levels. RESULTS- Acarbose treatment was associated with significantly greater reductions in HbA(1c) (-0.5 ± 02% vs. placebo 0.1 ± 0.2% [means ± SEM], P = 0.038), 1-h postprandial glucose (-2.3 ± 0.4 mmol/l vs. placebo 0.7 ± 0.4 mmol/l, P < 0.001) and body weight (-0.54 ± 0.32 kg vs. placebo 0.42 ± 0.29 kg, P < 0.05). There was no significant difference between the two groups regarding Changes in fasting plasma glucose and lipids or fasting and postprandial insulin levels. Flatulence was the most common side effect (acarbose vs. placebo: 28/45 vs. 11/44, P < 0.05). One patient on acarbose had asymptomatic elevations in serum transaminases that normalized in 4 weeks after acarbose withdrawal. Another patient on acarbose developed severe hypoglycemia; glycemic control was subsequently maintained on half the baseline dosage of sulfonylurea. CONCLUSIONS- In NIDDM patients inadequately controlled on conventional oral agents, acarbose in moderate doses resulted in beneficial effects on glycemic control, especially postprandial glycemia, and mean body weight. Additional use of acarbose can be considered as a useful alternative in such patients if they are reluctant to accept insulin therapy.
Persistent Identifierhttp://hdl.handle.net/10722/48972
ISSN
2015 Impact Factor: 8.934
2015 SCImago Journal Rankings: 5.827
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLam, KSLen_HK
dc.contributor.authorTiu, SCen_HK
dc.contributor.authorTsang, MWen_HK
dc.contributor.authorIp, TPen_HK
dc.contributor.authorTam, SCFen_HK
dc.date.accessioned2008-06-12T06:31:06Z-
dc.date.available2008-06-12T06:31:06Z-
dc.date.issued1998en_HK
dc.identifier.citationDiabetes Care, 1998, v. 21 n. 7, p. 1154-1158en_HK
dc.identifier.issn0149-5992en_HK
dc.identifier.urihttp://hdl.handle.net/10722/48972-
dc.description.abstractOBJECTIVE- To determine the efficacy of acarbose, compared with placebo, on the metabolic control of NIDDM patients inadequately controlled on maximal doses of conventional oral agents. RESEARCH DESIGN AND METHODS- In this three-center double-blind study, 90 Chinese NIDDM patients with persistent poor glycemic control despite maximal doses of sulfonylurea and metformin were randomly assigned to receive additional treatment with acarbose 100 mg thrice daily or placebo for 24 weeks, after 6 weeks of dietary reinforcement. Efficacy was assessed by changes in HbA(1c), fasting and 1-h postprandial plasma glucose and insulin levels, and fasting lipid levels. RESULTS- Acarbose treatment was associated with significantly greater reductions in HbA(1c) (-0.5 ± 02% vs. placebo 0.1 ± 0.2% [means ± SEM], P = 0.038), 1-h postprandial glucose (-2.3 ± 0.4 mmol/l vs. placebo 0.7 ± 0.4 mmol/l, P < 0.001) and body weight (-0.54 ± 0.32 kg vs. placebo 0.42 ± 0.29 kg, P < 0.05). There was no significant difference between the two groups regarding Changes in fasting plasma glucose and lipids or fasting and postprandial insulin levels. Flatulence was the most common side effect (acarbose vs. placebo: 28/45 vs. 11/44, P < 0.05). One patient on acarbose had asymptomatic elevations in serum transaminases that normalized in 4 weeks after acarbose withdrawal. Another patient on acarbose developed severe hypoglycemia; glycemic control was subsequently maintained on half the baseline dosage of sulfonylurea. CONCLUSIONS- In NIDDM patients inadequately controlled on conventional oral agents, acarbose in moderate doses resulted in beneficial effects on glycemic control, especially postprandial glycemia, and mean body weight. Additional use of acarbose can be considered as a useful alternative in such patients if they are reluctant to accept insulin therapy.en_HK
dc.format.extent418 bytes-
dc.format.mimetypetext/html-
dc.languageengen_HK
dc.publisherAmerican Diabetes Association. The Journal's web site is located at http://diabetes.diabetesjournals.org/en_HK
dc.relation.ispartofDiabetes Careen_HK
dc.rightsThis is an author-created, uncopyedited electronic version of an article accepted for publication in Diabetes Care[http://diabetes.diabetesjournals.org/] The American Diabetes Association (ADA), publisher of Diabetes Care, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version is available online at [http://diabetes.diabetesjournals.org/]en_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subject.meshDiabetes Mellitus, Type 2 - drug therapy - epidemiologyen_HK
dc.subject.meshHypoglycemic Agents - adverse effects - therapeutic useen_HK
dc.subject.meshMetformin - therapeutic useen_HK
dc.subject.meshSulfonylurea Compounds - therapeutic useen_HK
dc.subject.meshTrisaccharides - adverse effects - therapeutic useen_HK
dc.titleAcarbose in NIDDM patients with poor control on conventional oral agents: A 24-week placebo-controlled studyen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0149-5992&volume=21&issue=7&spage=1154&epage=1158&date=1998&atitle=Acarbose+in+NIDDM+patients+with+poor+control+on+conventional+oral+agents:+a+24-week+placebo-controlled+studyen_HK
dc.identifier.emailLam, KSL:ksllam@hku.hken_HK
dc.identifier.authorityLam, KSL=rp00343en_HK
dc.description.naturepublished_or_final_versionen_HK
dc.identifier.doi10.2337/diacare.21.7.1154en_HK
dc.identifier.pmid9653611-
dc.identifier.scopuseid_2-s2.0-0031850851en_HK
dc.identifier.hkuros37356-
dc.identifier.hkuros41476-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0031850851&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume21en_HK
dc.identifier.issue7en_HK
dc.identifier.spage1154en_HK
dc.identifier.epage1158en_HK
dc.identifier.isiWOS:000074416800022-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridLam, KSL=8082870600en_HK
dc.identifier.scopusauthoridTiu, SC=7003310747en_HK
dc.identifier.scopusauthoridTsang, MW=7102712282en_HK
dc.identifier.scopusauthoridIp, TP=55183685400en_HK
dc.identifier.scopusauthoridTam, SCF=7202037323en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats